JDQ443 in hepatic impairment

Phase 1, open-label trial of opnurasib in Small Cell Lung Cancer (SCLC) (4 arms), sponsored by Novartis. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration at 72 hours, Area Under the Plasma Concentration-time Curve From Time Zero to Infinity at 72 hours and 8 more. Started May 2022; status: completed.